is this you? Claim your profile.
is this you? Claim your profile.
Senior Vice President for Vaccine Development
HQ Phone:  (212) 847-1111
Direct Phone: (212) ***-****
+ Get 10 Free Contacts a Month
It's free and takes 30 seconds
125 BROAD ST
New York City, New York,10004
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996, IAVI works with partners ... more.
Senior Vice President of Vaccine Research and Development
Executive Vice President, Vaccine Research and Development
American Academy of Microbiology
National Foundation for Infectious Diseases
Wistar Institute Vaccine Center
Member of Advisory Board
Member, Supervisory Board
Panacos Pharmaceuticals Inc
Member of Scientific Advisory Board
State University of New York at Stony Brook
Postdoctoral Fellow In the Department of Microbiology
Cornell University Graduate School of Medical Sciences
Cornell University Graduate School
microbiology and genetics
IAVI Commemorates the Life of Dr. Ciro de Quadros, Former Board Member and Public Health Expert - IAVI - International AIDS Vaccine Initiative
Emilio Emini @gatesfoundation: Act now or risk #HIV rebounding @IAVIreporthttps://t.co/eFVi4Sxf4c
Emilio A. Emini
Emilio A. Emini, Ph.D., is Senior Vice President of Vaccine Research and Development at Pfizer Inc., a position into which he transitioned subsequent to Pfizer's acquisition of Wyeth Pharmaceuticals in late 2009. Dr. Emini joined Wyeth as Executive Vice President of Vaccine Research and Development in November 2005. At Wyeth, he led the R&D efforts that resulted in licensure of Prevnar 13, Pfizer's vaccine for the prevention of pneumococcal disease. Currently, Dr. Emini leads Pfizer's worldwide vaccine research and development programs. Dr. Emini joined the pharmaceutical industry in 1983 at the Merck Research Laboratories where he led the biological research that resulted in the development of one of the first highly active antiretroviral therapies for the treatment of HIV infection. As head of vaccine research at Merck, he participated in a number of vaccine development programs, including those that resulted in the licensure of the human papillomavirus and human rotavirus vaccines. Prior to joining Wyeth, Dr. Emini also served as Senior Vice President of Vaccine Development at the International AIDS Vaccine Initiative. Dr. Emini is also an Adjunct Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. In 2006, he was awarded the Distinguished Alumnus Award from the Cornell University Graduate School of Medical Sciences. He is a Fellow of the American Academy of Microbiology and a former Trustee of the National Foundation for Infectious Diseases. Dr. Emini also serves as a member of the National Biodefense Science Board, an advisory committee to the U.S. Secretary of Health and Human Services. Dr. Emini received his Ph.D. in Microbiology, Genetics and Biochemistry from the Cornell University Graduate School of Medical Sciences.
Emilio A. Emini, PhD, Senior Vice President, Vaccine Research and Development, Pfizer
Emilio A. Emini, Ph.D. is Senior Vice President and Head of Vaccine Research and development for Pfizer Inc. Dr. Emini joined Pfizer through Pfizer's acquisition of Wyeth where he served as Executive Vice President of Vaccine Research and Development. Before Wyeth, Emilio spent 21 years of his career at the Merck Research Laboratories as a research scientist, eventually becoming the founding Executive Director of Merck's Department of Antiviral Research and, subsequently serving as Vice President of Merck's Vaccine and Biologics Research with responsibility for the company's overall basic research portfolio in vaccines. In 2004 and 2005, Emilio served as Senior Vice President and Head of Vaccine Development at the International AIDS Vaccine Initiative. Dr. Emini is an Adjunct Professor of Pathology and Laboratory Medicine at the University Of Pennsylvania School Of Medicine. He is a Fellow of the American Academy of Microbiology, a former Trustee of the National Foundation for Infectious Diseases, and a member of Wistar Institute Vaccine Center's Advisory Board. He also serves as an active member of the National Biodefense Science Board.
Long-time pharmaceutical company veteran Emilio Emini took over the reins of the HIV program at the Bill & Melinda Gates Foundation over a year ago.
Here, he describes the Foundation's efforts to combat HIV and why this task is more important than ever. Since last July, the HIV program has been led by Emilio Emini, a seasoned pharmaceutical industry leader with decades of experience in both HIV research generally, and vaccine development in particular. During his career at Merck, Wyeth, and then Pfizer, Emini amassed experience in developing and licensing both drugs and complex vaccines. While at Merck, he led the research team that developed one of the first ARVs against HIV. He also led the company's vaccine development effort, helping usher HIV vaccine candidates into clinical trials and working on the development and licensure of their vaccines against rotavirus and human papilloma virus. His work in vaccines continued at Wyeth and Pfizer, where he led the effort that resulted in the licensure of the pneumococcal vaccine, Prevnar 13. In between his decades-long experience in the pharmaceutical industry, Emini also served as senior vice president of vaccine development at the International AIDS Vaccine Initiative (IAVI). In all these roles, Emini brought his vast experience, agile mind, and calm nature to bear on a daunting scientific challenge. In his current position, he remains as determined and practical as ever. When we spoke recently, he emphasized how important it is that efforts to stem the rate of new HIV infections in the hardest-hit places and populations continue to accelerate. "This is not the time to back off," he says. "I believe we are on the edge of losing control of the epidemic. This is the premise upon which we look at everything that we're trying to do. Accelerating a continuing decline in new infections requires sustained funding, improved access to existing treatment and prevention options, and more research into newer and better options to both treat HIV infection and prevent the virus's spread. And although the goal is ensuring that happens as quickly as possible, Emini understands the heftiness of the task.
ISV - International Society for Vaccines
Emilio Emini, Ph.D., is the HIV Program Director at Bill & Melinda Gates Foundation for the Global Health.
Dr. Emini was the Chief Scientific Officer and Senior Vice President of Vaccine Research at Pfizer Inc. Previously, Dr. Emini served as Senior Vice President and Head of Vaccine Development at the International AIDS Vaccine Initiative. He was also the founding Executive Director of Merck's Department of Antiviral Research and the Vice President of Merck's Vaccine and Biologics Research. Dr. Emini received his doctoral degree in 1980 from the Cornell University Graduate School of Medical Sciences in the fields of microbiology, genetics and biochemistry.